Acetyltryptophan

Acetyltryptophan

SCHEMBL1427071

CC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O.[NaH]

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.77
ACE P12821 3/20 0.72
ITGB2 P05107 3/20 0.69
ICAM1 P05362 3/20 0.69
ITGAL P20701 3/20 0.69
TACR1 P25103 1/20 0.68
ECE1 P42892 6/20 0.66
KDM4E B2RXH2 1/20 0.63
APAF1 O14727 1/20 0.63
POLB P06746 1/20 0.63
MAPT P10636 1/20 0.63
RECQL P46063 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
FPR2 P25090 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetyltryptophan SCHEMBL1304923 1.00 ALOX15 (0.77) ALOX15ACEITGB2ICAM1ITGAL
Acetyltryptophan SCHEMBL4216452 0.99 ALOX15 (0.79) ALOX15ACEITGB2ICAM1ITGAL
Acetyltryptophan SCHEMBL29401158 0.99 ALOX15 (0.79) ALOX15ACEITGB2ICAM1ITGAL
Acetyltryptophan SCHEMBL29360698 0.99 ALOX15 (0.79) ALOX15ACEITGB2ICAM1ITGAL
Acetyltryptophan SCHEMBL57141 0.99 ALOX15 (0.79) ALOX15ACEITGB2ICAM1ITGAL
Acetyltryptophan SCHEMBL4216450 0.99 ALOX15 (0.79) ALOX15ACEITGB2ICAM1ITGAL
Acetyltryptophan SCHEMBL57140 0.99 ALOX15 (0.79) ALOX15ACEITGB2ICAM1ITGAL
Acetyltryptophan SCHEMBL702442 0.99 ALOX15 (0.79) ALOX15ACEITGB2ICAM1ITGAL
Acetyltryptophan SCHEMBL23933298 0.97 ALOX15 (0.77) ALOX15ACEITGB2ICAM1ITGAL
Acetyltryptophan SCHEMBL11471931 0.97 ALOX15 (0.77) ALOX15ACEITGB2ICAM1ITGAL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025126144-A1 METHODS OF MONITORING PARAMETERS IN SOLUTION CSL BEHRING AG (CH) 2025-06-19 WO claimed
CN-119498281-A Bovine embryo cryopreservation method and thawing method thereof 北京九州大地生物技术集团股份有限公司 2025-02-25 CN claimed
CN-119184064-A Bovine oocyte cryoprotectant and cryopreservation method 北京九州大地生物技术集团股份有限公司 2024-12-27 CN claimed
CN-113549653-B Combination reagent for long-term storage of lentiviral vectors 上海赛比曼生物科技有限公司 2024-03-22 CN claimed
CN-117180441-A Platelet dehydration and drying protective agent, platelet dehydration and drying preparation and preparation method thereof 北京朴汇细胞生物科技有限公司 2023-12-08 CN claimed
US-20230141382-A1 COMPOSITIONS FOR PRESERVATION OF VIRAL VECTORS AbelZeta Inc. 2023-05-11 US claimed
EP-4139438-A1 COMPOSITIONS FOR PRESERVATION OF VIRAL VECTORS Cellular Biomedicine Group Inc. (US) 2023-03-01 EP claimed
WO-2021216989-A1 COMPOSITIONS FOR PRESERVATION OF VIRAL VECTORS CELLULAR BIOMEDICINE GROUP HK LIMITED (CN) 2021-10-28 WO claimed
CN-113549653-A Combination reagents for long-term storage of lentiviral vectors 上海赛比曼生物科技有限公司 2021-10-26 CN claimed
CN-113347974-A Compositions and methods of use of 2- (4-chlorophenyl) -N- ((2- (2, 6-dioxopiperidin-3-yl) -1-oxoisoindolin-5-yl) methyl) -2, 2-difluoroacetamide 细胞基因公司 2021-09-03 CN claimed
CN-110092827-A A kind of purification process obtaining high-purity recombination human serum albumin 齐智 2019-08-06 CN claimed
CN-110075073-A A kind of Cabazitaxel protein nano injection and preparation method thereof 深圳市健开医药有限公司 2019-08-02 CN claimed
CN-106692950-A Recombinant human albumin preparation for treating bedsores and preparation technology of recombinant human albumin preparation 华北制药秦皇岛有限公司 2017-05-24 CN claimed
CN-105188737-A Process for producing diketopiperazines and compositions containing diketopiperazines AMPIO PHARMACEUTICALS INC 2015-12-23 CN claimed
CN-102006872-A Ophthalmic preparation containing a pyridinol derivate MARVEL LIFESCIENCES LTD 2011-04-06 CN claimed
CN-1648134-A Dog intravenous injection albumin, its preparing method and dog intravenous injection albumin preparation FIELD BLOOD TRANSFUSION INST A (CN) 2005-08-03 CN claimed
EP-4739416-A1 METHOD OF PURIFICATION CSL Behring AG (CH) 2026-05-13 EP disclosed
US-20260007632-A1 FORMULATIONS OF DOCETAXEL ZHUHAI BEIHAI BIOTECH CO LTD (CN) 2026-01-08 US disclosed
US-4380646-A Method for the N-acylation of aminocarboxylic acids DYNAMIT NOBEL AKTIENGESELLSCHAFT (DE) 1983-04-19 US disclosed
US-4182904-A Method of racemizing optically active N-acyl amino acids in aqueous solution DYNAMIT NOBEL AKTIENGESELLSCHAFT (DE) 1980-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260007632-A1 FORMULATIONS OF DOCETAXEL ALB, TTR, SLC20A1 ALOX15 3575/4885ACE 3975/4885ITGB2 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.